Cancer-focused biotech GTx (GTXI +7.1%) moves higher on double its 10-day average volume after...

|By:, SA News Editor

Cancer-focused biotech GTx (GTXI +7.1%) moves higher on double its 10-day average volume after Stifel Nicolaus initiates coverage with a Buy rating citing "a potentially significant value-creating event … with the pending Enobosarm Phase 3 data." Price target is $7, representing a 40% upside from the stock's current price.